Antisense Therapeut (ANP) Short Interest
Antisense Therapeut (ASX:ANP) had 0.00% of shares reported as short positions as of 24 July 2023, representing 256 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Antisense Therapeut
Antisense Therapeutics is a biotechnology company focused on developing RNA-based therapies for rare and debilitating genetic disorders. The company leverages antisense technology to create treatments that target specific genetic sequences, offering a unique approach to disease management. Positioned in the niche market of genetic disorder therapeutics, Antisense aims to address unmet medical needs with its innovative pipeline.
Short position
Antisense Therapeut (ASX:ANP) has 0.00% of its shares on issue reported as short positions as of 24 July 2023, or about 256 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.35% in September 2013. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4ANP intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Antisense Therapeut.
About
website
Be the first to discuss ANP
Start a research thread or post the first pulse update